Members of the investor and media communities will find a number of tools and resources below. Please click on the respective links to access our investor toolbox or the media center.
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.
Santhera has a worldwide license to vamorolone, a first-in-class dissociative steroid, for all indications which is currently investigated in the pivotal study VISION-DMD in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids.
The clinical stage pipeline also includes POL6014 to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies.
Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.